Tag: Richard Lowenthal

neffy®

FDA Accepts New Drug Application for Nasal Epinephrine Spray Treatment for...

If approved, acceptance targeted for mid-2023.
Neffy Intranasal Epinephrine Device

CEO Expects Approval and Launch of Intranasal Emergency Epinephrine Spray by...

The market for epinephrine delivery may expand to include non-needle alternatives next year.
Intranasal Spray

Emergency Epinephrine Nasal Spray Takes Final Step Toward Approval in EU

A needle-free option for administration of epinephrine is on the horizon.
Neffy Intranasal Epinephrine Device

ARS Pharmaceuticals Announces New Patent on ARS-1 (Epinephrine Nasal Spray)

Intranasal delivery of emergency epinephrine takes another step closer to becoming a reality.
Nose

ARS to Present Data from Intranasal Epinephrine (ARS-1) Studies at AAAAI...

Neffy™ (formally ARS-1) was fast-tracked by the FDA in 2019 as an intranasal alternative to epinephrine auto-injectors.
Nose

FDA Fast Tracks ARS-1 Intranasal Epinephrine Spray

Company provides a novel means of administering emergency epinephrine.